JSPR today
$14.76+$0.01 (+0.07%)close Nov 11, 2026Trend
DailyUptrend (confirmed)
4 hourStrong Bullish
1 hourSymmetric Triangle
15 minDescending Triangle
5 minDescending Triangle
Daily trend turns down below $0.44
Key levels
Resistance$19.92
Resistance$17.03
Support$7.19
Support$5.67
Latest news & SEC filings
NewsJasper Therapeutics Reports Outcome of Its Warrant Buyback Offer
All JSPR news →About Jasper Therapeutics
Jasper Therapeutics is a clinical-stage biotechnology company developing therapies for diseases driven by mast cells, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma. Its main drug candidate, briquilimab, is an antibody that blocks stem cell factor from binding to the KIT receptor found on mast and stem cells. The company operates in the United States and licenses rights from Amgen and Stanford University for development and commercialization.
Based on the company's 10-K filed Mar 30, 2026.
Nasdaq · Healthcare
Jasper Therapeutics, Inc. (JSPR)
What Is the Price Target for JSPR?
SEPT Low Target
$2.12
SEPT Mid Target
$2.50
SEPT High Target
$2.88
Analyst Consensus
$2.50
Is JSPR a Buy or Sell Right Now?
Thesis
- •SEC filings signal active product innovation — 1 new product/expansion keywords detected in 10-K. R&D investment rising.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for JSPR.
Start Free Trial →Is JSPR Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B, PEG, Analyst Consensus
Fair Value
$1.79
5
Moat Score
NONE
0/9
Piotroski Score
-19.2
Altman Z-Score
What Is Smart Money Doing with JSPR?
Insider Signal
NEUTRAL
0 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
LOW
Signal: NEUTRAL
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →JSPR Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
19.22%
FCF Growth YoY
N/A%
Revenue Trend
UNKNOWN
Dark Pool Trades for JSPR
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for JSPR, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 18:23:33 | $14.55 | 1,494 | $$22K | BUY |
| 16:46:02 | $14.33 | 1,000 | $$14K | BUY |
| 16:06:58 | $14.30 | 1,600 | $$23K | BUY |
| 20:23:58 | $14.30 | 1,167 | $$17K | BUY |
| 16:51:26 | $15.03 | 1,000 | $$15K | SELL |
5 dark pool trades shown · $$91K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Jasper Therapeutics, Inc. (JSPR) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →JSPR — frequently asked questions
What is JSPR stock price today?
Jasper Therapeutics, Inc. (JSPR) is at $14.76, up 0.07% (+$0.01) at the Nov 11, 2026 close.
Why is JSPR stock moving today?
Latest JSPR news — Nov 10, 2026: Jasper Therapeutics Reports Outcome of Its Warrant Buyback Offer
What is the JSPR price target?
The average analyst price target for JSPR is $2.50, ranging from $2 to $3, based on 2 analysts. Latest: Piper Sandler initiates on Aug 12, 2026.
What do analysts rate JSPR?
Analyst ratings for JSPR: 0 Buy, 3 Hold, 1 Sell — consensus Hold.
Did JSPR beat earnings?
JSPR last reported on Aug 14, 2026: EPS -$0.10 vs -$0.27 expected — a beat of 62.7%.
Does JSPR pay a dividend?
JSPR does not currently pay a dividend.
What are JSPR support and resistance levels?
Support: $7.19, $5.67, $4.00. Resistance: $17.03, $19.92, $22.52.
What are insiders doing with JSPR?
Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.
What is the latest news on JSPR?
Nov 10, 2026: Jasper Therapeutics Reports Outcome of Its Warrant Buyback Offer